GERN
Geron Corporation
$1.12
-0.88%
2026-10-23
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Key Fundamentals
Forward P/E
31.50
EPS (TTM)
$-0.11
ROE
-28.3%
Revenue Growth (YoY)
17.2%
Profit Margin
-33.1%
Debt/Equity
55.87
Price/Book
3.71
Beta
0.60
Market Cap
$809.5M
Avg Volume (10D)
10.6M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.65
60D Low
$1.08
Avg Volume
10.0M
Latest Close
$1.12
Get breakout alerts for GERN
Sign up for Breakout Scanner to receive daily notifications when GERN triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Geron Corporation (GERN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GERN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GERN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.